Thyroid Hormone Receptor Agonists for THRβ-Selective Metabolic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing thyroid hormone treatments for conditions like obesity, hyperlipidemia, and cardiovascular diseases often cause undesirable effects such as hyperthyroidism and hypothyroidism, necessitating the development of thyroid hormone analogs that maintain beneficial effects while avoiding these adverse outcomes.
Innovation Solution
Development of novel thyroid hormone receptor ligands, represented by compounds of Formula (I) or (I′), which modulate thyroid hormone receptor activity to treat conditions like obesity, metabolic diseases, and cardiovascular diseases, including liver diseases, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thyroid hormone treatments are administered to treat conditions like obesity, hyperlipidemia, and cardiovascular diseases, then beneficial therapeutic effects are achieved, but undesirable effects such as hyperthyroidism and hypothyroidism occur
Solution Approach 1:
The patent applies local quality by designing compounds that selectively activate thyroid hormone receptor beta (THRβ) in specific tissues (liver, adipose tissue, muscle) while avoiding activation in the heart. This tissue-selective activation achieves therapeutic benefits for metabolic diseases without causing cardiac adverse effects associated with non-selective THR activation
Solution Approach 2:
The patent segments the thyroid hormone receptor activation function by developing compounds with differential selectivity for THRα and THRβ isoforms. By prioritizing THRβ selectivity, the invention separates the metabolic benefits (mediated by THRβ) from the cardiac side effects (associated with THRα activation), allowing independent optimization of therapeutic effects
2Productivity
If naturally occurring thyroid hormones or thyromimetic analogues are administered for hormone replacement, then metabolic rate and oxygen consumption increase, but adverse effects on heart and bone function occur
Solution Approach 1:
The patent employs local quality by creating compounds with enhanced tissue selectivity, particularly for liver and adipose tissue expression of THRβ. This selective activation increases metabolic rate and oxygen consumption in target tissues while minimizing activation in cardiac and skeletal tissues, thereby avoiding adverse effects on heart and bone function
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of thyroid hormone analogs to alter their binding affinity and selectivity profile. By optimizing molecular parameters such as substituent groups on the phenolic ring and adjusting the iodine atom position, the compounds achieve higher THRβ selectivity and reduced THRα activation, thereby improving the therapeutic index
Data Source
AI summary
The application relates to a compound of Formula (I′) or (I):or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.